We are live on ! Find out more
GNRX

VanEck Vectors Generic Drugs ETF
GNRX

Delisted

GNRX was delisted on the 4th of April, 2019.

Back to rankings

0 hedge funds and large institutions have $0 invested in VanEck Vectors Generic Drugs ETF in 2019 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $414K → $0 (-$414K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
–
Holders Change
-3
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$257K
2
APA
American Portfolios Advisors
New York
-$142K
3
UBS Group
UBS Group
Switzerland
-$15K
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
1
Susquehanna International Group
Pennsylvania
– -$257K -11,614 Closed
APA
2
American Portfolios Advisors
New York
– -$142K -6,419 Closed
UBS Group
3
UBS Group
Switzerland
– -$15K -660 Closed

GNRX Hedge Fund Activity: Q2 2019 in Review

0 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in VanEck Vectors Generic Drugs ETF (GNRX) for Q2 2019, worth a combined $0 — down 100% from $414K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of GNRX and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Susquehanna International Group, exiting entirely with an estimated $257K sold.

  • 0 institutional investors held VanEck Vectors Generic Drugs ETF (GNRX) as of Q2 2019, down from 3 in Q1 2019.
  • Funds reported $0 of VanEck Vectors Generic Drugs ETF stock for Q2 2019, down 100% quarter-over-quarter.
  • 0 funds opened new VanEck Vectors Generic Drugs ETF positions in Q2 2019 and 3 closed out, a net change of -3 holders.
  • The largest VanEck Vectors Generic Drugs ETF seller in Q2 2019 was Susquehanna International Group, an estimated $257K sold.

Based on aggregated 13F filings for Q2 2019.